|
Antimicrobial agent
| |
A. baumannii(n = 101)
|
P. aeruginosa(n = 15)
|
|---|
|
Breakpoint forresistancea(mg/L)
|
%Resistance
|
Range(mg/L)
|
MIC50(mg/L)
|
MIC90(mg/L)
|
Breakpoint forresistancea(mg/L)
|
%Resistance
|
Range(mg/L)
|
MIC50(mg/L)
|
MIC90(mg/L)
|
|---|
|
Amikacin
|
≥64
|
85
|
<2- > 1024
|
>1024
|
>1024
|
≥64
|
60
|
<2- > 1024
|
64
|
>1024
|
|
Arbekacin
|
-
|
-
|
<2- > 1024
|
>1024
|
>1024
|
-
|
-
|
2- > 1024
|
2
|
>1024
|
|
Aztreonam
|
-
|
-
|
<2- > 256
|
128
|
>256
|
≥32
|
46
|
4- > 256
|
16
|
>256
|
|
Ceftazidime
|
≥32
|
55
|
<4- > 512
|
>512
|
>512
|
≥32
|
46
|
<4- > 512
|
16
|
>512
|
|
Ciprofloxacin
|
≥4
|
98
|
<1- > 128
|
128
|
>128
|
≥4
|
66
|
<1-64
|
8
|
32
|
|
Colistin
|
≥4
|
6
|
<0.25-4
|
2
|
2
|
≥8
|
0
|
<0.25-0.5
|
<0.25
|
0.5
|
|
Gentamicin
|
≥16
|
91
|
<2- > 1024
|
>1024
|
>1024
|
≥16
|
66
|
<2- > 1024
|
256
|
>1024
|
|
Imipenem
|
≥16
|
48
|
<4-128
|
16
|
32
|
≥8
|
53
|
<4-64
|
16
|
32
|
|
Meropenem
|
≥16
|
51
|
<4- > 256
|
32
|
64
|
≥8
|
53
|
<4-32
|
16
|
32
|
|
Piperacillin
|
≥128
|
100
|
<4- > 512
|
>512
|
>512
|
≥128
|
46
|
<4- > 512
|
32
|
256
|
|
Piperacillin/Tazobactam
|
≥128/4
|
52
|
<4- > 512
|
256
|
512
|
≥128/4
|
13
|
<4-512
|
32
|
128
|
-
aBreakpoints for antimicrobial resistance were determined according to the guidelines of the Clinical and Laboratory Standards Institute (M07-A9).
